| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q1 2023 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALLOGENE THERAPEUTICS, INC. | 7 | Q2 2020 | 88.8% |
| HOMOLOGY MEDICINES, INC. | 7 | Q2 2020 | 13.5% |
| SUTRO BIOPHARMA, INC. | 7 | Q2 2020 | 8.7% |
| OYSTER POINT PHARMA, INC. | 2 | Q2 2020 | 30.8% |
| OYSTER POINT PHARMA, INC. | 1 | Q4 2019 | 18.8% |
View VV Manager LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2020-08-04 |
| 13F-HR | 2020-04-10 |
| 13F-HR | 2020-01-08 |
| 13F-HR | 2019-10-15 |
| 13F-HR | 2019-07-10 |
| 13F-HR/A | 2019-04-11 |
| 13F-HR | 2019-04-11 |
| 13F-HR | 2019-02-27 |
| 4 | 2018-04-04 |
View VV Manager LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.